Search Results for: "janssen v celltrion"

Janssen v. Celltrion Appeal Docketed

The appeal from Janssen Biotech, Inc. v. Celltrion Healthcare Co. (D. Mass. No. 15-10698) has been docketed at the Federal Circuit with the number 17-1120.  Janssen’s opening brief is due on December 27, 2016.  We have posted extensively on the district court case, most recently here, and will continue to post on…

Read More

Janssen v. Celltrion: Janssen Appeals Judgment Invalidating the ’471 Patent

As we previously reported, on September 26, 2016, the district court in Janssen v. Celltrion entered partial final judgment that the ’471 patent, asserted by Janssen, was invalid.  Today, Janssen filed a notice that they are appealing the district court’s judgment to the Federal Circuit. Meanwhile, Celltrion’s partner Pfizer announced last week that it will begin shipping…

Read More

Litigation Update: Motions in Janssen v. Celltrion for Entry of Final Judgment and Case Scheduling

  As we posted previously, the District Court in Janssen v. Celltrion has ruled that the ‘471 patent is invalid for obviousness-type double patenting on the two grounds raised in the defendants’ motions for summary judgment on that patent. The defendants last week moved for an entry of final judgment on the plaintiffs’ infringement allegations for the…

Read More

Update in Janssen v. Celltrion: Parties Stipulate that Celltrion Will Not Sell Remicade Biosimilar Before October 3, 2016

In a stipulation filed yesterday in Janssen v. Celltrion, Celltrion has agreed not to sell its Remicade biosimilar in the U.S. for use by doctors or patients before October 3, 2016, and the parties have agreed to dismiss all claims and defenses related to Defendants’ alleged violation of the BPCIA’s 180-day notice of commercial marketing provision (42…

Read More

Celltrion Begins Shipping Remsima to the U.S.

As we reported last week,  the district court granted Celltrion’s Motion for Summary Judgment of Invalidity for one of the two patents-at-issue in Janssen v. Celltrion.  The Korea Times reports that Celltrion shipped its first batch of its Remicade biosimilar, Remsima, to the U.S. on August 19th, the day after the ruling. Please continue to…

Read More